Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases

ConclusionIn this large-scale, healthcare claims database analysis, AD patients had a significantly higher comorbidity burden, HCRU, and costs compared with matched non-AD controls. Higher disease severity was associated with an even greater comorbidity and economic burden.FundingSanofi and Regeneron Pharmaceuticals, Inc.

Source: Advances in Therapy - July 13, 2017 Category: Drugs & Pharmacology Source Type: research